Study: NCT01818011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 Initial fit for purpose tablets
Description: Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 over granulated tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 intended commercial tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 intended commercial tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 intended commercial tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-GSK1322322 stable isotope powder
Description: White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 for injection
Description: White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 for injection
Description: White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C